Page last updated: 2024-11-10

decaprenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

geranoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

geranic acid : A polyunsaturated fatty acid that is octa-2,6-dienoic acid bearing two methyl substituents at positions 3 and 7 (the 2E-isomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

decaprenoic acid: synthetic isoprenoid; RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5275520
CHEMBL ID170190
CHEBI ID67264
SCHEMBL ID358253
MeSH IDM0126945
PubMed CID5312583
CHEBI ID195801
SCHEMBL ID310619
MeSH IDM0126945

Synonyms (92)

Synonym
MLS000516004
smr000112472
geranoic acid
2,6-octadienoic acid, 3,7-dimethyl-
459-80-3
geranic acid
nsc-229335
nsc229335
wln: qv1uy1&3uy1&1
ai3-12136
3,7-dimethyl-2,6(and 2,7)-octadienoic acid
einecs 207-299-9
3,7-dimethylocta-2,6-dienoic acid
nsc 229335
brn 1763804
2,6-octadienoic acid, 3,7-dimethyl-, (2e)-
(2e)-3,7-dimethylocta-2,6-dienoic acid
geranic acid, 85%, stabilised
geranic acid, technical grade, 85%
CHEMBL170190
chebi:67264 ,
LMFA01030784
3,7-dimethyl-2e,6-octadienoic acid
(2e)-3,7-di-methyl-octa-2,6-di-enoic acid
NCGC00247010-01
unii-pl902ikn0a
pl902ikn0a ,
3-02-00-01469 (beilstein handbook reference)
dtxcid8027115
tox21_302708
NCGC00256752-01
cas-459-80-3
HMS2269B05
unii-10797g3m5y
geranic acid, (2e)-
10797g3m5y ,
4698-08-2
(e)-3,7-dimethylocta-2,6-dienoic acid
geranilyc acid
trans-3,7-dimethyl-2,6-octadien-1-oic acid
trans-geranic acid
trans-geranoic acid
AKOS015893966
geranic acid a
2,6-octadienoic acid, 3,7-dimethyl-, (e)-
(e)-geranic acid
geranic acid, trans-
fema no. 4121, e-
geranic acid, (e)-
SCHEMBL358253
58x ,
DTXSID10109997
mfcd00036493
geranic acid, 90% (sum of isomers)
(2e)-geranic acid
Q4381113
mfcd20542837
A851142
BS-42293
EN300-761337
neric acid
nerolic acid
decaprenoic acid
LMFA01030440
3,7-dimethyl-2z,6-octadienoic acid
3,7-dimethyl-2z,6e-octadienoic acid
CHEBI:195801
(2z)-3,7-dimethylocta-2,6-dienoic acid
(z)-3,7-dimethylocta-2,6-dienoic acid
4613-38-1
AKOS016004982
neryl acid
cis-geranic acid
2,6-octadienoic acid, 3,7-dimethyl-, (2z)-
geranic acid, (2z)-
fema no. 4121, z-
geranic acid, (z)-
2,6-octadienoic acid, 3,7-dimethyl-, (z)-
6k8mfd7k03 ,
(z)-geranic acid
geranium acid
neranic acid
unii-6k8mfd7k03
geranic acid b
SCHEMBL310619
(2z)-3,7-dimethyl-2,6-octadienoic acid
DTXSID90109995
(z)-3,7-dimethyl-2,6-octadienoic acid
geraniumsaure
Q18391807
EN300-7429959
CS-0217418
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
pheromoneA semiochemical used in olfactory communication between organisms of the same species eliciting a change in sexual or social behaviour.
EC 1.14.18.1 (tyrosinase) inhibitorAny EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosinase (monophenol monooxygenase), EC 1.14.18.1, an enzyme that catalyses the oxidation of phenols (such as tyrosine) and is widespread in plants and animals.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
melanin synthesis inhibitorA depigmentation agent which inhibits the synthesis of melanin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
polyunsaturated fatty acidAny fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
methyl-branched fatty acidAny branched-chain fatty acid containing methyl branches only.
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
thioredoxin glutathione reductaseSchistosoma mansoniPotency56.23410.100022.9075100.0000AID485364
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency66.67120.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.87510.000229.305416,493.5996AID743069
serine-protein kinase ATM isoform aHomo sapiens (human)Potency39.81070.707925.111941.2351AID485349
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency70.79460.050127.073689.1251AID588590
Guanine nucleotide-binding protein GHomo sapiens (human)Potency56.23411.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID47226In vitro inhibition of yeast-to-hypha transition in candida albicans; No inhibition2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID1519392Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519395Antibacterial activity against Enterococcus hirae ATCC 10541 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519394Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519396Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519393Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519391Antibacterial activity against Staphylococcus aureus NCTC 4163 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519398Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519397Antibacterial activity against Escherichia coli NCTC 8196 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID47395In vitro inhibition of yeast cell growth of candida albicans at a concentration of 100 ug/mL2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID1519399Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.63)18.7374
1990's1 (2.63)18.2507
2000's8 (21.05)29.6817
2010's17 (44.74)24.3611
2020's11 (28.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]